Navigation Links
Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
Date:2/3/2010

PITTSBURGH, Feb. 3 /PRNewswire/ -- An era of personalized medicine is redefining how patients and doctors work together to fight cancer.  Now, drug response markers such as the ChemoFx® diagnostic test show promising results which can help to determine individual cancer treatment plans when using various chemotherapeutic agents.

ChemoFx® is a test produced by Precision Therapeutics, Inc., a life sciences company in Pittsburgh, Pennsylvania. With the introduction of this innovative drug response marker, the company has pioneered a method of identifying cancer cell response and sensitivity to various chemotherapeutic and biologic agents at the biopsy stage -- long before a patient actually begins chemotherapy -- providing a custom blueprint of a patient's probable tumor response.

The result is valuable insight into which chemotherapy drugs are most likely to work in an individual cancer patient's own body -- along with those that are unlikely to be effective in shrinking and killing the cancerous tumor.  This information can then be used to help guide chemotherapy treatment decisions, according to company officials.

"Patients and their physicians will have an understanding of how chemo will impact the cancer cells themselves long before it impacts the patient," says Sean McDonald, CEO of Precision Therapeutics.  "By testing multiple agents on a patient's cancer cells in the lab, ChemoFx® determines the chemotherapies that are more likely to be effective and avoid those that are likely to be ineffective, giving patients a powerful advantage in their fight against cancer."

The diagnostic test works by taking a sample of a patient's tumor, which is removed during biopsy or surgery, and sending that sample to the Precision Therapeutics laboratory for sensitivity and resistance testing. In a controlled environment that closely parallels what happens within the human body itself, those cells are incubated and treated by a fully automated system with a number of chemotherapy and biologic agents selected by that patient's physician.  Precision Therapeutics then sends the physician a report that details how the cancerous cells responded to each drug or chemotherapy combination. Integrating the results with clinical judgment, the physician can then use the report to support his decision on a treatment regimen for the patient, with the tandem objective of eradicating the disease and optimizing quality of life during chemotherapy treatment.

With the national movement toward cancer patient advocacy gaining momentum, those newly diagnosed are now engaging with their treating physician as both patient -- and partner -- in making cancer treatment decisions.  

"Today's cancer patients are informed, empowered self advocates," according to McDonald.  "They want a voice in their own treatment options.  A key discussion points is the topic of personalizing medicine through testing services such as ChemoFx.  Each and every patient's cancer is unique, making the need for individual, custom drug response markers all the more critical to support a patient's treatment plan. They want their first step to be the right step."

"When you're diagnosed with cancer, your strongest ally is information," says McDonald.  "That means talking with your doctor to plan your best course of action together.  We encourage you to test the tumor first, find out how it responds, and based on those findings and your physicians clinical judgment, determine the optimal treatment plan for your individual cancer."

About Precision Therapeutics

Precision Therapeutics, a life science company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions.

For more information, please visit www.precisiontherapeutics.com or www.ChemoFX.com

SOURCE Precision Therapeutics, Inc.

RELATED LINKS
http://www.precisiontherapeutics.com

'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
4. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
5. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
6. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
7. Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
8. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
9. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
10. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
11. Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
Breaking Medicine News(10 mins):